Endo and Mersana unite to create antibody-drug conjugates

03/7/2012 | American City Business Journals

Mersana Therapeutics and Endo Pharmaceuticals Holdings agreed to jointly develop antibody-drug conjugates to treat cancer. The partners will bind Endo's antibody candidates to existing chemotherapy agents using Mersana's Fleximer technology. In addition to an upfront payment, Mersana could get as much as $270 million in milestone fees, plus sales royalties.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care